Anixa completes fifth cohort dosing in ovarian cancer trial

Anixa Biosciences (NASDAQ:ANIX) completed dosing the fifth cohort in its Phase 1 trial for ovarian cancer, with no dose-limiting toxicities observed. The fifth cohort received the highest dose yet, and one patient showed stable disease 90 days post-treatment. The sixth cohort will evaluate an even higher dose. The trial, conducted at Moffitt Cancer Center, aims to assess safety, tolerability, and preliminary efficacy.

Original reporting
Published Oct 26, 2026, 12:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 1:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$ANIX
Bullish
medium confidence
Mentioned
$ANIX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ANIXBullishLow
01

Why it matters

The announcement provides the first safety readout for the highest dose level, showing no dose‑limiting toxicities and a case of stable disease, which may improve short‑term sentiment but remains early‑stage.

02

Market read

The news is a primary disclosure of early clinical data for a micro‑cap biotech, offering modest upside potential but limited immediate trading impact.

03

What to watch

Regulatory timelines and the competitive landscape for ovarian cancer CAR‑T therapies could temper enthusiasm.

Relevance 8/10Novelty 8/10Timing: today

Background

Anixa Biosciences (NASDAQ:ANIX) is developing a CAR‑T therapy targeting the follicle‑stimulating hormone receptor for recurrent ovarian cancer. The company announced the completion of dosing for its fifth cohort, the highest dose tested to date.

Company-level read

Ticker impact

$ANIXBullishMedium confidence
Context

Anixa Biosciences completed dosing of the fifth cohort in its Phase 1 CAR‑T ovarian cancer trial, reporting no dose‑limiting toxicities and stable disease in the first patient.

Expected impact

modest upward pressure as investors price in encouraging safety signals

Evidence & confidence

First‑time reporting of higher dose level and absence of toxicities is new information; however, efficacy is still limited and the cohort size is tiny, so any price move is likely modest.

Market effects

Adds a data point for the CAR‑T oncology sector, potentially supporting other early‑stage biotech peers.

Limited to U.S. biotech investors; no broader regional effect.

Minor global impact; primarily relevant to specialty biotech investors.

Counterpoint

The trial is still early and the sample size is too small to justify any price rally; investors may wait for Phase 2 data.

Key entities

  • Anixa Biosciences Inc.

    Developer of the CAR‑T therapy in question.

  • Moffitt Cancer Center

    Site conducting the Phase 1 trial.

Related articles

$ANIXMedAI 8/10

Anixa ovarian cancer trial to be presented at ESMO congress

Anixa Biosciences (NASDAQ:ANIX) will present Phase 1 trial results for its ovarian cancer treatment at the ESMO congress. The trial, led by Dr. Robert Wenham, evaluates the safety and efficacy of liraltagene autoleucel, a CAR-T therapy. The company reported no dose-limiting toxicities, stable disease in one patient, and over one-year survival in four patients. Anixa plans to advance to a sixth cohort with a 1,000-fold dose increase.

$ANIXMedAI 8/10

Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026

Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Robert Wenham will present Phase 1 trial results of its CAR-T therapy for ovarian cancer at the ESMO Congress in December 2026. The trial, conducted at Moffitt Cancer Center, has completed its fifth cohort with no dose-limiting toxicities and encouraging preliminary results. The company plans to advance to a sixth cohort with a higher dose.

$ANIXMedAI 8/10

Four patients have survived over a year after treatment, one beyond two years. Anixa's trial will be presented Dec. 14.

Anixa Biosciences reported positive interim results from its Phase 1 trial of lira-cel, a CAR-T therapy for ovarian cancer. Four patients survived over a year, one beyond two years. The company plans to advance to a sixth cohort with a 1,000-fold dose increase. Results will be presented at the ESMO Immuno-Oncology & Advanced Therapies Congress on Dec. 14.

$ANIXMedAI 8/10

Four ovarian cancer patients lived over a year after Anixa's experimental treatment.

Anixa Biosciences' experimental ovarian cancer treatment, lira-cel, showed promising results in a Phase 1 trial, with four patients surviving over a year. Dr. Jose Conejo-Garcia, who invented the technology, will present findings at the 2026 Ovarian Cancer Midwest Focus Conference. The trial, conducted with Moffitt Cancer Center, has not reported dose-limiting toxicities, and one patient has survived beyond two years.

$ANIXMedAI 8/10

H.C. Wainwright reiterates Buy on Anixa stock, $6 target on trial data

H.C. Wainwright reiterated a Buy rating and $6 target on Anixa Biosciences (ANIX) after positive trial data. The stock trades at $2.95, with analysts' targets ranging from $6 to $14. The company reported stable disease in a patient from its Phase 1 trial of lira-cel for ovarian cancer. ANIX holds a strong financial position with a current ratio of 8.54 and more cash than debt. The firm expects further trial updates soon.